Physician profile
Blake Allen Baird
NPI 1982607743
$1,448.15
in general payments reported to CMS, 2019-2025
20 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.37 · 2020: $144 · 2021: $265 · 2022: $96.07 · 2023: $202 · 2024: $282 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $843.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $277.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $255.69 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $236.10 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $228.68 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $89.79 | 2019-2021 | |
| Astellas Pharma US INC | $80.12 | 2019-2024 | Veozah |
| Ultragenyx Pharmaceutical INC. | $37.17 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $35.94 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.21 | 2020-2024 | Jardiance |
| Inspire Medical Systems, INC. | $25.12 | 2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.90 | 2025 | Xifaxan |
| Amgen INC. | $18.10 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $17.74 | 2021 | |
| Sunovion Pharmaceuticals INC. | $16.40 | 2022 | |
| Merck Sharp & Dohme LLC | $15.94 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $15.21 | 2021 | |
| Esperion Therapeutics, INC. | $14.34 | 2021 | |
| Dexcom, INC. | $13.73 | 2023 | Dexcom G6 Transmitter |
| Nabriva Therapeutics, Plc | $13.11 | 2021 | |
| Glaxosmithkline, LLC. | $13.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Baird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.